This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Epidermolysis Bullosa Dystrophica
and you are
over 18
years old
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.
Tris trial is registered with FDA with number: NCT00904163. The sponsor of the trial is Stanford University and it is looking for 13 volunteers for the current phase.
Official trial title:
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa